Next Article in Journal
Gold Nanoparticles Modulate BCG-Induced Innate Immune Memory in Human Monocytes by Shifting the Memory Response towards Tolerance
Previous Article in Journal
Tannic Acid Promotes TRAIL-Induced Extrinsic Apoptosis by Regulating Mitochondrial ROS in Human Embryonic Carcinoma Cells
 
 
Review

Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors

by 1,2 and 1,2,*
1
College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU), Qatar Foundation, Education City, P.O。 Box 34110 Doha, Qatar
2
Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), P.O. Box 34110 Doha, Qatar
*
Author to whom correspondence should be addressed.
Cells 2020, 9(2), 283; https://doi.org/10.3390/cells9020283
Received: 3 January 2020 / Revised: 16 January 2020 / Accepted: 17 January 2020 / Published: 23 January 2020
(This article belongs to the Section Stem Cells)
Diabetes mellitus (DM) is one of the most prevalent metabolic disorders. In order to replace the function of the destroyed pancreatic beta cells in diabetes, islet transplantation is the most widely practiced treatment. However, it has several limitations. As an alternative approach, human pluripotent stem cells (hPSCs) can provide an unlimited source of pancreatic cells that have the ability to secrete insulin in response to a high blood glucose level. However, the determination of the appropriate pancreatic lineage candidate for the purpose of cell therapy for the treatment of diabetes is still debated. While hPSC-derived beta cells are perceived as the ultimate candidate, their efficiency needs further improvement in order to obtain a sufficient number of glucose responsive beta cells for transplantation therapy. On the other hand, hPSC-derived pancreatic progenitors can be efficiently generated in vitro and can further mature into glucose responsive beta cells in vivo after transplantation. Herein, we discuss the advantages and predicted challenges associated with the use of each of the two pancreatic lineage products for diabetes cell therapy. Furthermore, we address the co-generation of functionally relevant islet cell subpopulations and structural properties contributing to the glucose responsiveness of beta cells, as well as the available encapsulation technology for these cells. View Full-Text
Keywords: hPSCs; hyperglycemia; insulin-secreting cells; β-cell precursors; pancreatic islets; transplantation hPSCs; hyperglycemia; insulin-secreting cells; β-cell precursors; pancreatic islets; transplantation
Show Figures

Figure 1

MDPI and ACS Style

Memon, B.; Abdelalim, E.M. Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors. Cells 2020, 9, 283. https://doi.org/10.3390/cells9020283

AMA Style

Memon B, Abdelalim EM. Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors. Cells. 2020; 9(2):283. https://doi.org/10.3390/cells9020283

Chicago/Turabian Style

Memon, Bushra, and Essam M. Abdelalim. 2020. "Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors" Cells 9, no. 2: 283. https://doi.org/10.3390/cells9020283

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop